Latest news

Extension of preclinical research collaboration agreement with a top-10 large pharma company

Posted on Jul 22, 2019

Oslo (Norway), 22 July 2019 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that they are extending the preclinical research collaboration with an undisclosed top-10 pharma company. The pharma company is one of the global leaders in nucleic acid therapeutics and the collaboration was initiated in September 2015. The aim of […]

PCI Biotech to present at IPA World Congress

Posted on Jul 3, 2019

Oslo, Norway, July 1, 2019 PCI Biotech (OSE:PCIB), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present the company at the International Photodynamic Association (IPA) World Congress in Boston, US. PCI Biotech will be represented by Per Walday (CEO), Hans Olivecrona (CMO) and Anders Høgset (CSO) who […]

Employee share option scheme

Posted on Jun 21, 2019

Oslo, 21 June 2019 – In accordance with the authorisation granted by the Annual General Meeting 29 May 2019, the Board of Directors of PCI Biotech Holding ASA has awarded a total of 320,000 share options to key employees. Each share option gives the right to subscribe for or acquire one share per option (after PCI […]